Cephalon hires FDA free agent
This article was originally published in The Tan Sheet
Executive Summary
Victor Raczkowski, former director for FDA's Office of Drug Safety, joins Cephalon as VP-regulatory affairs. Cephalon is embattled in a bidding war with aaiPharma to acquire CIMA Labs (1"The Tan Sheet" Sept. 22, 2003, In Brief). Raczkowski is the second ODS director to leave the agency for an industry position; Peter Honig joined Merck as VP-risk management in February 2002 (2"The Tan Sheet" Jan. 21, 2002, p. 23)...
You may also be interested in...
CIMA Labs reconsiders
CIMA Labs says "there is a reasonable likelihood" that an unsolicited acquisition offer from Rx drug maker Cephalon "would reasonably be expected to result in a superior proposal" to an already-agreed upon stock-swap transaction with aaiPharma, according to a Sept. 19 release. Cephalon sent a letter to CIMA's board on Sept. 10 asking them to reconsider their decision to reject the Rx firm's proposal (1"The Tan Sheet" Sept. 15, 2003, p. 7). aaiPharma remains "committed" to completing the merger with CIMA, the company said in a statement...
FDA Drug Safety Office Losing Honig, But Gaining FTEs
FDA is looking for a new director for its fledgling Office of Drug Safety following the departure of Peter Honig, MD, to Merck
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.